BMRN
Biomarin Pharmaceutical Inc
61.40$
-1.4%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +11.2% | +0.4% | +9.7% | +4.7% | +0.2% | -0.3% | +10.8% | -6.0% | +12.7% | -12.4% | +29.2% | – | |
| – | +5.8% | -7.6% | +4.2% | +44.5% | -27.8% | +11.3% | -1.0% | -6.7% | +110.7% | -33.9% | +4.0% | – | |
| – | +12.7% | +2.5% | +11.1% | -4.2% | +9.7% | -2.9% | +13.8% | -5.8% | -8.9% | -1.4% | +37.8% | – | |
| – | +7.8% | -0.6% | -10.3% | +0.6% | -6.2% | -8.5% | +1.6% | +153.8% | -53.0% | -7.1% | +15.7% | – | |
| – | +179.7% | -24.9% | +31.6% | +3.1% | -2.5% | -26.5% | +6.4% | +24.4% | +485.0% | -83.4% | +89.9% | – | |
| – | +17.4% | -12.4% | +6.0% | -3.8% | +1.4% | -17.8% | +7.8% | +71.4% | -26.8% | -11.7% | +53.1% | – | |
| – | -53.4% | +522.1% | +36.2% | -5.4% | +41.7% | +38.7% | +23.7% | -116.9% | – | +63.3% | -14.4% | – | |
| – | +61.4% | -41.8% | +0.8% | -17.0% | -13.2% | +11.1% | -6.4% | -3.7% | +7.7% | +438.4% | +323.2% | – | |
| – | -53.6% | +446.1% | +25.2% | +1.7% | +26.2% | +40.4% | +25.1% | -108.8% | – | – | -56.5% | – | |
| – | -181.2% | – | +47.8% | +13.6% | +57.6% | +17.2% | +9.4% | -92.3% | +339.4% | +83.7% | -53.4% | – | |
| – | -49.5% | +335.2% | +20.9% | -1.0% | +17.8% | +48.6% | +29.5% | -112.8% | – | – | -57.6% | – | |
| – | -27.3% | +164.0% | +18.9% | -3.6% | +25.0% | +34.5% | +21.3% | -101.6% | – | – | +28.8% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.